Image Image Image Image Image Image Image Image Image Image
Access
Up

Up

CHROMA: Clinical Trial of Lampalizumab for Geographic Atrophy Secondary to Age-Related Macular Degeneration 29/01/2015

AG_assaigCHROMA

 

Description

Phase III clinical studies have been initiated for Lampalizumab, an investigational drug for geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD), a progressive condition which can result in blindness. The phase III study program will evaluate the safety and efficacy of Lampalizumab and its potential to slow the progression of GA. The studies will also further explore if people with a specific genetic biomarker, a mutation in complement factor I, may benefit more from Lampalizumab treatment.

These phase III trials, called Chroma (GX29176) and Spectri (GX29185), are identically-designed, double-masked, randomized studies evaluating 10 mg dose of Lampalizumab administered every 4 or 6 weeks by intravitreal injection to sham injections. Approximately 936 patients will be enrolled in each study from approximately 300 physician-investigator sites in 24 countries worldwide.

Key inclusion criteria

Include the presence of geographic atrophy in both eyes with no history of neovascular (wet) AMD.

Objectives

The primary objective is to demonstrate a reduction in the rate of GA disease progression. This efficacy endpoint, evaluated at one year, is defined as the mean change in the GA lesion area of the chosen study eye from baseline.

Secondary objectives, planned for evaluation at two years, focus on assessing the impact of Lampalizumab treatment on patients’ visual function. If successful, it is planned to continue through a subsequent, open-label extension study.

 

About Lampalizumab

Lampalizumab, developed by Roche (Basel, Switzerland), is being investigated to determine its effect on the progression of GA associated with advanced AMD.

_MG_8162

 

If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155. 
Our team of professionals will answer you as soon as possible and we will assess whether you are eligible. 

Intravitreal injectionsDry or atrophic AMD

Author

Dr. Jordi Monés, M.D., Ph.D.
COMB Medical license number: 22.838
Director
Doctor of Medicine and Surgery
Specialist in Ophthalmology
Specialist in Retina, Macula and Vitreorretinal

Last modified: 12 November, 2019 - 18:15